Literature DB >> 1509305

Economic appraisal of asthma and COPD care: a literature review 1980-1991.

M P Mölken1, E K Van Doorslaer, F F Rutten.   

Abstract

Despite the considerable burden and costs of illness and despite the increasing need to set priorities on the basis of efficiency considerations, only 20 economic appraisals of asthma and COPD care have been published during the past 11 years. This paper provides a detailed summary of the cost-effectiveness 'evidence' given by these studies and a discussion of relevant methodological issues. The studies comparing programme costs of delivery methods for oxygen and for aerosol bronchodilator drugs, provide the most straightforward evidence in favour of the concentrator and the metered dose inhaler respectively. There also seems to be evidence in favour of hospital-based home care programmes as compared to community-based home care programs. Health education, especially directed at asthmatic children seems to reduce health care costs and improve attitude, compliance behaviour and self-management skills. Information on the cost-effectiveness of pharmacotherapy and diagnostic technologies, both important interventions in asthma and COPD, was found to be totally lacking.

Entities:  

Mesh:

Year:  1992        PMID: 1509305     DOI: 10.1016/0277-9536(92)90163-k

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  11 in total

1.  Quality-of-life outcomes and the use of antihistamines in a French national population-based sample of patients with perennial rhinitis.

Authors:  P D Pariente; C LePen; F Los; J Bousquet
Journal:  Pharmacoeconomics       Date:  1997-11       Impact factor: 4.981

2.  The episode-free day as a composite measure of effectiveness: an illustrative economic evaluation of formoterol versus salbutamol in asthma therapy.

Authors:  M J Sculpher; M J Buxton
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

Review 3.  The economic costs of asthma: a review and conceptual model.

Authors:  K B Weiss; S D Sullivan
Journal:  Pharmacoeconomics       Date:  1993-07       Impact factor: 4.981

4.  Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.

Authors:  Michael Spencer; Andrew H Briggs; Ronald F Grossman; Laureen Rance
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Cost effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator monotherapy in children with asthma.

Authors:  M P Rutten-van Mölken; E K Van Doorslaer; M C Jansen; E E Van Essen-Zandvliet; F F Rutten
Journal:  Pharmacoeconomics       Date:  1993-10       Impact factor: 4.981

6.  Secondary analysis of economic data: a review of cost-benefit studies of neonatal screening for phenylketonuria.

Authors:  J Lord; M J Thomason; P Littlejohns; R A Chalmers; M D Bain; G M Addison; A H Wilcox; C A Seymour
Journal:  J Epidemiol Community Health       Date:  1999-03       Impact factor: 3.710

Review 7.  Budesonide. An appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in asthma.

Authors:  R Davis; D McTavish
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

Review 8.  Assessing quality of life in chronic non-specific lung disease--a review of empirical studies published between 1980 and 1994.

Authors:  A R Maillé; A A Kaptein; J C de Haes; W T Everaerd
Journal:  Qual Life Res       Date:  1996-04       Impact factor: 4.147

9.  Psychological distress and depressed mood in employees with asthma, chronic bronchitis or emphysema: a population-based observational study on prevalence and the relationship with smoking cigarettes.

Authors:  Edwin J Wagena; Ijmert Kant; Marcus J H Huibers; Ludovic G P M van Amelsvoort; Gerard M H Swaen; Emiel F M Wouters; Constant P van Schayck
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

10.  Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model.

Authors:  Ann C Wu; A David Paltiel; Karen M Kuntz; Scott T Weiss; Anne L Fuhlbrigge
Journal:  J Allergy Clin Immunol       Date:  2007-09-29       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.